Chang David D 4
4 · Allogene Therapeutics, Inc. · Filed May 26, 2021
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2021-05-24$18.22/sh+27,410$499,410→ 2,312,279 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-05-24−27,410→ 541,190 totalExercise: $18.22Exp: 2030-03-18→ Common Stock (27,410 underlying)
Holdings
- 1,201,108(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]Securities held in the name of the Chang 2006 Family Trust.
- [F2]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F3]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- [F4]25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.